Candel Therapeutics, Inc. SEC filings CADL

Candel Therapeutics, Inc. has 418 filings in SEC EDGAR's recent list, going back to Feb 16, 2021. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 10, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 29, 2026 Dec 31, 2025
10-K Annual report Mar 12, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 29, 2025 Dec 31, 2024
10-K Annual report Mar 13, 2025 Dec 31, 2024
ARS Annual report to shareholders May 30, 2024 Dec 31, 2023
10-K/A Amended annual report Apr 25, 2024 Dec 31, 2023
10-K Annual report Mar 28, 2024 Dec 31, 2023
ARS Annual report to shareholders May 23, 2023 Dec 31, 2022
10-K/A Amended annual report May 1, 2023 Dec 31, 2022
10-K Annual report Mar 30, 2023 Dec 31, 2022
10-K Annual report Mar 29, 2022 Dec 31, 2021

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CADL (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Needham, MA
SEC filer status
, Emerging growth company
SEC CIK
1841387

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.